Abbott's Kaletra Needs Stronger Warnings To Discourage Off-Label Use In Neonates, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's combination protease inhibitor causes serious toxicity in newborns, the agency will tell its Pediatric Advisory Committee.
You may also be interested in...
Non-Psychiatric Prescribing Fuels Rise In Antidepressant Use, Study Finds
Use of antidepressants has become concentrated in patients who have less severe and poorly defined medical conditions, according to an 11-year survey published in Health Affairs.
Flu Vaccine Demand Forecast: Flat Or Up Slightly Compared With Last Year
The five providers of the six approved seasonal influenza vaccines appear to be preparing for a similar season with similar sales in 2011-12 as they had last year.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.